Vaccine-Resistant Ebola Strain Spreads in Uganda
The Wall Street Journal - October 04, 2022
Kartik Chandran, Ph.D., talks about the need for medical professionals to be ready for future outbreaks of Ebola by working on novel vaccines and drugs that are effective against numerous strains of the virus, rather than only one strain. Dr. Chandran is professor of microbiology & immunology and the Harold and Muriel Block Faculty Scholar in Virology at Einstein.
Additional coverage includes The New York Times and Nature
The Omicron Variant is Surging. Here's What We've Learned So Far
Science News - December 21, 2021
Kartik Chandran, Ph.D., says the omicron variant of the coronavirus that causes COVID-19 may be both more transmissible and better able to evade the immune response than previous variants, although more data is needed. Dr. Chandran is professor of microbiology & immunology and the Harold and Muriel Block Faculty Scholar in Virology.
Omicron Arrives On the Scene
KNX In Depth - November 29, 2021
Kartik Chandran, Ph.D., says there is much to learn about the new COVID-19 variant, omicron, including if it is more likely to cause severe disease or spread more easily that currently dominant variants. He notes the importance of vaccination and getting booster shots to protect against the virus. Dr. Chandran is professor of microbiology & immunology and the Harold and Muriel Block Scholar in Virology at Einstein. (Interview begins at 1:22)
What's Ahead for SARS-CoV-2 Research in 2021
The Scientist - January 08, 2021
Kartik Chandran, Ph.D., talks about the future of COVID-19 research, including the development of treatments and vaccines to treat and prevent the novel coronavirus as it mutates over time. Dr. Chandran is professor of microbiology & immunology and the Harold and Muriel Block Scholar in Virology at Einstein.
The Coronavirus is Mutating. What Does That Mean for Us?
The New York Times - December 20, 2020
Kartik Chandran, Ph.D., comments on a highly contagious new variant of the coronavirus, noting the body produces numerous antibodies that will make it difficult for the virus to escape a full immune system response. Dr.Chandran is professor of microbiology & immunology and the Harold and Muriel Block Scholar in Virology at Einstein.
Additional Coverage includes The Scientist
The Race for a Super-Antibody Against the Coronavirus
The New York Times - October 12, 2020
Kartik Chandran, Ph.D., describes the efforts of a multi-institutional collaboration he is leading to discover a potent, long-lasting antibody that would be effective against a range of coronaviruses, not only the one that causes COVID-19. Dr. Chandran is professor of microbiology & immunology and the Harold and Muriel Block Scholar in Virology at Einstein.
First Ebola Treatment Approved by FDA
Chemical & Engineering News - October 11, 2020
Kartik Chandran, Ph.D., comments on the importance of developing antibody treatments for Ebola and other emerging viruses. Dr. Chandran is professor of microbiology & immunology and the Harold and Muriel Block Scholar in Virology at Einstein.
Wall Street Journal interviews Kartik Chandran, Ph.D., and Steven Walkley, D.V.M., Ph.D., about the connection between the rare genetic disease Niemann-Pick Type C (NPC) and Ebola. Dr. Chandran’s research suggests that the gene mutation responsible for NPC may offer protection against Ebola. Dr. Walkley notes that it is well-known that carriers of certain genetic diseases might have protection against other diseases, citing that carriers for sickle-cell disease might be protected against malaria. Dr. Chandran is associate professor of microbiology & immunology and holds the Harold and Muriel Block Faculty Scholar in Virology. Dr. Walkley is director of the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center and professor of pathology, of neurology and of neuroscience at Einstein. (subscription only)
More coverage on this story
The Scientist
CBSNews.com
November 3, 2014